Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-thymocyte globulin (Thymoglobulin Thymo) in combination with tacrolimus and sirolimus (TTS) in 47 patients (pts) for the prevention of acute and chronic GvHD after unrelated AHSCT. The median follow-up was 45.2 months. The cumulative incidence of NIH severe cGvHD at 48 months was 6.4% with no new occurrences past 6 months for the entire follow-up period. The overall cumulative incidence of cGvHD was 44.7%. Out of 20 pts who are alive and disease-free at the last follow-up, only 4 pts continue to need systemic immune suppression. We observed low late NRM with only 3 transplant-related deaths after 6 months post transplant. At 4 years of follow-up, the overall cumulative incidence of NRM and disease relapse was 27.7% and 30.0%, respectively. PFS and overall survival (OS) at 4 years were 42 and 47%. At long term follow-up, TTS was associated with low incidence of severe cGvHD and late NRM.
INTRODUCTION
Chronic GvHD (cGvHD) is a syndrome of dysregulated immunity with combined features of autoimmunity and immunodeficiency, both of which contribute to its morbidity and mortality. 1 It remains one of the main challenges for patients (pts) who survive three months post allogeneic hematopoietic stem cell transplantation (AHSCT). The overall incidence of cGvHD has been reported to be 50-76%, and that of extensive cGvHD to be 45-48% with the use of peripheral blood hematopoietic stem cells (PBSC). 2, 3 cGvHD is the main cause for late non-relapse mortality and morbidity post transplant. [4] [5] [6] Severe cGvHD, (as defined by the NIH scoring system 7 ) affects 27-32% of patients and is associated with increased late non-relapse mortality (NRM) and decreased overall survival, as shown in three different large retrospective studies. [8] [9] [10] Some studies have shown that cGvHD contributes to better graft versus leukemia effect (GvL) and therefore confers less risk of relapse. [11] [12] [13] However, other studies contended that the protective effects of cGvHD occurred during early post-transplant period and lasting effect is only seen in certain diseases such as CML. 5 Furthermore active cGvHD itself and the need for long term immune suppression can affect multiple organs leading to long term morbidity and significant impact on functional capacity which are ongoing challenges. 14, 15 Historically factors associated with cGvHD are: aGvHD, female donors, recipient age 420 years, and most recently the use of PBSC graft. 2, 16 A recent study showed an increasing incidence of cGvHD which could be attributed to increasing use of older donors and PBSC for AHSCT. 17 Since aGvHD is the most commonly associated risk factor for cGvHD, most prophylaxis regimens are aimed at reducing aGvHD in order to mitigate the risk of cGvHD. One such combination is tacrolimus and sirolimus (Tac/Siro). 18, 19 In a randomized phase III trial which compared Tac/Siro to the standard regimen of Tac and methotrexate (Tac/MTX), there was statistically significant improvement in severe aGvHD in the Tac/Siro arm, but no improvement in overall aGvHD, cGvHD or survival. 20 Another approach to prevent cGvHD is non pharmacologic with the addition of anti-thymocyte globulin (ATG) in various preparations and doses to Tac/MTX. 21, 22 Three recent phase III trials tested the addition of rabbit ATG-Fresenius to cyclosporin/MTX in the setting of sibling donor in one trial, and unrelated donor transplants in the two others. All trials showed a significant reduction in the incidence of acute, chronic, and severe chronic GvHD with no improvement in survival. 3, 23, 24 Based on these promising results, we combined intermediate dose rabbit ATG Thymoglobulin (Genzyme, Cambridge, MA, USA) (Thymo) with Tac/Siro in a phase II trial. We reported a low incidence of grade 2-4 aGvHD of 23%, and grade 3-4 aGvHD of 11%. 25 Here we show that this combination not only was effective in preventing aGvHD, but it resulted in low rate of severe cGvHD, low late NRM, high KPS without evident effect on the expected relapse rate.
MATERIALS AND METHODS
We previously reported early results from this phase II GvHD prevention trial using Thymo/Tac/Siro in patients undergoing unrelated AHSCT. We now report on a pre-planned analysis of long term outcomes. This trial was approved by Wayne State University Institutional Review Board and all patients signed informed consents. The trial was registered at clinical trials. gov #NCT00691015. The primary end point of the trial was to assess the incidence and severity of aGvHD based on the consensus grading scale. 26 Secondary end points included: safety of this combination defined as grade III or higher non-hematologic toxicities as per the Common Terminology Criteria for Adverse Events (CTCAE v3) and NRM in the first 6 months post transplant. Additional secondary end points included: time to absolute neutrophil and platelet engraftment, incidence of infections including CMV, EBV reactivation and post-transplant lymphoproliferative disorder (PTLD), incidence of thrombotic microangiopathy (TMA) and sinusoidal obstructive syndrome (SOS), incidence and severity of cGvHD using NIH consensus, 7 Karnofsky performance status (KPS), overall survival (OS) and PFS.
Eligibility for the trial required a diagnosis of a hematologic malignancy including myelodysplastic syndromes (MDS) and myeloproliferative disorders. Patients without HLA-matched sibling donors were eligible if they had a suitable HLA 8/8 (A, B, C and DR) or 7/8 allele matched unrelated donor. Disease diagnosis, risk definitions, supportive care, organ function requirement, and preparative regimens have been described before. 25 Thymo/Tac/Siro GvHD prophylactic regimen consisted of a total dose of Thymo of 4.5 mg/kg in divided doses. (day − 3: 0.5 mg/kg, day − 2: 1.5 mg/kg, and day − 1: 2.5 mg/kg). Tac and Siro were started on day − 3 as described before. 
Statistical method
Descriptive analyses for baseline characteristics were performed. Binary outcomes were estimated using proportions and the Wilson's 95% confidence interval (95% CI). The cumulative incidence of cGvHD and immune suppression therapy (IST) free was calculated with disease relapse or death without GvHD as competing risks. The Kaplan-Meier estimator was used to calculate RFS (defined as the time from BMT to relapse or progression or death from any cause), OS (defined as the time from BMT to death from any cause), and EFS (defined as time from BMT to the earliest event of relapse, or death due to any cause, or cGvHD if failed IST independence). For immune correlative studies, to visualize the trend among the reconstitution markers, the medians of each marker at multiple time points (day 30, 60, 90 and 180 post AHSCT) were plotted along the time line. Side-by-side box of immune reconstitution markers were plotted in subgroups of clinical outcomes, independently, such as aGvHD (yes/no), cGvHD (yes/no), relapse (yes/no) at each time point. As the goal of this analysis is to identify any immune predictors for clinical outcomes, at any specific time point, clinical outcomes that occurred before marker measurement were excluded. Hence, the sample size decreases when time from BMT increases. A two-sample t test on log2 transformed data was used for evaluating the association between markers and clinical outcomes. All P-values are two-sided and not adjusted for multiple testing due to the nature of this exploratory study. Statistical analysis was performed using R version 3.2.2.
RESULTS

Patient characteristics
As shown in Table 1 , 15 male pts (32% of total) received their PBSC grafts from a female donor. About half of the pts received PBSC graft from a 7/8 HLA-matched donors, while the other half received it from an 8/8 HLA-matched donor. A total of 33 patients (70%) had high risk disease for relapse and death as defined in our previous report. 25 Thirty four pts (72%) received high intensity preparative regimens, while 13 pts (28%) received reduced intensity regimens.
Incidence and severity of cGvHD The cumulative incidence (incidence) of cGvHD for evaluable patients was 36.2 at 12 months, 42.6 at 24 months and 44.7% at 48 months (95% confidence interval (CI), 29.8-58.5%) as in Figure 1 . The incidence of severe cGvHD (NIH grade) was 6.4% (CI, 1.6-15.9%) and did not increase past 6 months for the entire follow-up period as in Figure 2 . There were 12 mild, 6 moderate and 3 severe cGvHD pts based on NIH grading. Three evaluable 
pts developed bronchiolitis obliterans, one of them was severe. Chronic GvHD severity and organ distribution is shown in Table 2 . Out of 35 pts alive at 6 months 21 developed cGvHD. Additional 5 pts with cGvHD were not evaluable (cGvHD was preceded by relapse and withdrawal of immune suppression). In order to compare our results with those from randomized phase III GvHD prevention trials, we re-analyzed the cumulative incidence of cGvHD based on the old grading system of limited/extensive. -100% ), while 54% (7/13: CI, 29-77%) had cGvHD when the donor was a male (Fisher's exact P-value = 0.046). We observed no correlation between HLA mismatch and development of cGvHD (9 cGvHD pts received their transplant from 7/8 HLA-matched donor and 12 from 8/8 HLA-matched donors), nor between the occurrence of aGvHD and cGvHD (9 pts had aGvHD before cGvHD, while 12 did not).
Non-relapse mortality Out of 35 pts alive after 6 months only 3 died from non-relapse reasons including (one from aGvHD, one from cGvHD and one from secondary graft failure). One patient relapsed early after transplant, but then died from cGvHD in CR. There were no infections as the primary cause of death for the whole trial. The incidence of NRM was 25.5% at 12 months, 27.7% at 24 months and 48 months (CI, 15.7-41%) as in Figure 2a .
Relapse and relapse patterns The cumulative incidence of relapse was 19.1% at one year, 21.3% at 12 months, and 30% at 48 months (CI, 17.5-43.6%) as in Figure 2b . Out of 14 total relapses on trial, 7 occurred beyond 6 months and 4 beyond 2 years. All but one relapse occurred in high risk pts as defined in our previous report. 25 Six pts relapsed with preceding cGvHD, while 8 pts relapsed without cGvHD. Of interest is that all four late relapses (42 years) happened in patients with cGvHD. Only 3 relapses were preceded by CMV viremia, two of which happened in pts who received grafts from CMV seronegative donors. Nine relapses happened in pts who received high intensity preparative regimen, while 5 occurred in pts with reduced intensity regimens. Three pts who relapsed were alive at the last analysis at 5, 9 and 25 months post relapse. Figure 3a . The EFS (defined as time from BMT to the earliest event of relapse, or death due to any cause or cGvHD if failed IST independence) at 12, 24 and 48 months was 45% (CI, 32-61%), 40% (CI, 29-57%) and 34% (CI, 23-51%). Total deaths after 6 months at the last follow-up were 12, with relapse being the main cause (n = 9), one aGvHD, one cGvHD and one late death due to secondary graft failure. Table 3 shows causes of death for the entire follow-up period. The incidence of being alive and immune suppression therapy (IST) free was 40% at 2 years and 46.1% (CI, 30.2-60.6%) at 48 months of follow-up as in Figure 3b . This cumulative incidence did not take in account disease progression or death which happened after the time point of successfully stopping immune suppression. At the last follow-up, only 4/20 alive and disease free patients continue to need IST. The median KPS (Karnofsky performance status) for the whole cohort was 80% at 6 months and 90% at 2 years post transplant. (Supplementary Figure 1) .
Immune reconstitution in the first 6 months post transplant We noticed an overall lymphopenia in the first six months post transplant with progressive recovery of CD8+ T cells, with very slow recovery of CD4 T cells, B cells, and natural killer (NK) cells as shown in Figure 4a . We further observed a rise in NK cell activation marker NKP30 (CD337) on day 60 post transplant as in Figure 4b . Finally, we noticed a trend towards an association between higher numbers of B cells at days 30 and 90 post transplant with higher chance of subsequent relapse as in Figures 4c and d .
DISCUSSION
We report long term outcomes of a phase II trial with the combination of Thymo/Tac/Siro for GvHD prophylaxis. We demonstrate low incidence of severe and extensive cGvHD of 6.4% and 31.9%, respectively. We believe that the low cGvHD severity has led to low late NRM with flat NRM curve after 18 months, as well as high incidence of immune suppression independence and recovery of functional capacity. Our overall incidence of cGvHD and extensive cGvHD was lower than the incidence and/or the proportion reported by multiple retrospective data sets and phase III trials except when ATG was used, as shown by Sailard et al. and Socie et al. (Table 4) . 3, 9 Our incidence and proportion of severe cGvHD as per NIH criteria was lower than that reported by multiple large retrospective data sets. [8] [9] [10] 27 Three of these data sets demonstrated a correlation between severe cGvHD and worse overall survival (Table 4) . [8] [9] [10] In our study the only cGvHD risk factor we observed was having a female donor to a male recipient. We did not observe a correlation between HLA mismatch and cGvHD. While this might be secondary to the efficacy of the GvHD regimen being used but a larger sample size is needed to confirm this finding.
Our overall NRM incidence is lower than several GvHD prevention phase III trials and one large retrospective study (Table 4) . 2, 3, 27, 28 Most of the our NRM was in the early posttransplant phase and mostly due (aGvHD, TMA, VOD). When we analyzed Tac/Siro levels, we concluded in the last report that most of those complications were potentially avoidable with closer monitoring and maintaining Siro level between 3-9, Tac between 5-10 ng/mL as well as carefully monitoring the interaction between azoles and Tac/Siro levels. 29 We noticed no death related to infection as the primary cause for the whole trial patients. Of interest we show very low late NRM after 6 months likely related to a low incidence of severe cGvHD, which compares very favorably to large retrospective studies. 6, 17 Our relapse rate was comparable with other GvHD prevention phase III randomized trials and with published CIBMTR rates of relapse despite the fact that 70% of the pts were at high risk for relapse. Relapse was the main cause of death in this trial. We did not observe any specific pattern of relapse except that all relapses beyond 2 years post transplant were in pts with cGvHD, which in a way supports the notion that the relapse-protective effects of cGvHD occurred during early post-transplant period. 5 Only three relapses were preceded with CMV reactivation, two of which happened with a CMV negative donor. Some evidence in the literature suggests that both post-transplant CMV reactivation and transplant from CMV seropositive donor can confer protection from relapse. [30] [31] [32] [33] We interpret these observations with caution, given our small sample size. Abbreviations: SOS, sinusoidal occlusive syndrome; TMA, thrombotic microangiopathy; VOD, veno-occlusive disease.
Low incidence of severe cGvHD and late NRM with TTS regimen Z Al-Kadhimi et al
Our immune reconstitution analysis showed profound lymphopenia and reversal of CD4/CD8 ratios in the first 6 months post transplant which was reported before. 31 Of interest we observed no initial rise in NK cells in the in the early phase post transplant as reported in the context of the use of ATG for GvHD prophylaxis. 34, 35 The likely cause is the use of sirolimus which is known to be a powerful inhibitor for NK cell proliferation. 36 More robust early total lymphocyte reconstitution post transplant and specifically more innate immune cell reconstitution have been shown to correlate with less relapse and better post-transplant survival. 35, 37, 38 Overall we demonstrated that that Thymo/Tac/Siro GvHD prophylaxis regimen resulted in low incidence of aGvHD, severe cGvHD, low late NRM and good functional capacity. Despite these advantages and the possibility of further lowering early NRM with better drug level monitoring, relapse remains a major challenge. Given the profound immune suppressive effect of sirolimus, one possible future option is to shorten the sirolimus exposure period to allow for earlier immune reconstitution. We hypothesise that GvHD prevention platform should not add to the transplant preparative regimen toxicity, lead to transient intense immune suppression at the critical time of GvHD initiation, and result in a robust innate and subsequent adaptive immune recovery to help prevent subsequent relapses and improve overall survival.
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